Skip to main content

BB Biotech Value Stock - Dividend - Research Selection

BB Biotech AG

ISIN: CH0038389992, WKN: A0NFN3

Market price date: 13.01.2021
Market price: 78,15 CHF

BB Biotech AG Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 24-04-2020
Cash flow
Net operating cash flow 213.778.000
Capital Expenditures -1
Free cash flow 213.778.000
Balance sheet
Total Equity 3.393.000.000
Liabilities & Shareholders equity 3.555.000.000
Income statement
Net income 677.430.000
Eps (diluted) 12,230
Diluted shares outstanding 55.390.800
Net sales/revenue 240.870.000

Fundamental ratios calculated on: 13-01-2021

Key figures 13-01-2021
Cash flow
P/C 20,25
P/FC 20,25
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization4.417.305.600,00 USD
IndicesPrime All Share
SectorsHealth service
Raw Data SourceIFRS in Millionen CHF
Stock Split2001-05-18,10.0000/1.0000

Description of the company

Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors.


Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a Westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.


Furthermore, many pharmaceutical giants are confronted with deep cuts in revenue streams as a result of patent expirations. They are now purchasing innovative biotech products in an attempt to replenish product pipelines and have been willing to pay top dollar in these deals.


Meanwhile every second drug approved today stems from the labs of a biotech company and many biotech firms have been reporting strong sales and profit growth. The biotech industry has obviously come of age and reached a certain level of maturity.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,